Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V
scheduling · Rule · Final rule. · Published 2017-03-09 · 82 FR 13067
Document
Document number
2017-04698
Federal Register citation
82 FR 13067
Type
Rule
Action
Final rule.
Category
scheduling
Publication date
2017-03-09
Abstract
This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12, 2016. The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015.